瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06938 瑞博生物-B

未开盘 03-03 16:08:27

61.000

-3.250

-5.06%

最高64.950	最低59.000	成交量29.14万
今开64.300	昨收64.250	日振幅9.26%
总市值104.04亿	流通市值104.04亿	总股本1.71亿
成交额1,771万	换手率0.17%	流通股本1.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":61,"timestamp":1772525307556,"preClose":64.25,"halted":0,"volume":291400,"delay":0,"changeRate":-0.05058365758754864,"floatShares":170554910,"shares":170554910,"eps":-1.855,"marketStatus":"未开盘","change":-3.25,"latestTime":"03-03 16:08:27","open":64.3,"high":64.95,"low":59,"amount":17714520,"amplitude":0.092607,"askPrice":61,"askSize":3400,"bidPrice":59.15,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.502,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772587800000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":64.25,"openAndCloseTimeList":[[1772501400000,1772510400000],[1772514000000,1772524800000]],"volumeRatio":1.3010090181396072,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"1165985607","title":"瑞博生物-B启动RBD7022注射液治疗高脂血症III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1165985607","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165985607?lang=zh_cn&edition=full","pubTime":"2026-03-02 08:11","pubTimestamp":1772410268,"startTime":"0","endTime":"0","summary":"瑞博生物-B（股票代码：06938）近日宣布，其研发的RBD7022注射液将在中国正式启动针对高脂血症治疗的III期临床试验。该试验旨在进一步评估该药物在更广泛患者群体中的安全性与有效性，标志着其在心血管代谢疾病治疗领域的研发进程迈入关键阶段。高脂血症作为常见的心血管风险因素，其创新疗法的推进备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2616877702","title":"瑞博生物-B(06938)：RBD7022注射液即将于中国启动用于治疗高血脂症适应症的 III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2616877702","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616877702?lang=zh_cn&edition=full","pubTime":"2026-03-02 08:11","pubTimestamp":1772410260,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)公布，集团自主研发的RBD7022注射液已由合作方齐鲁制药有限公司(齐鲁制药)完成III期临床试验登记公示，即将启动III期临床试验。RBD7022注射液是一款靶向PCSK9的siRNA药物。PCSK9是一种酶，在调节体内胆固醇，尤其是通常被称为“LDL-C”或“坏胆固醇”的低密度脂蛋白(LDL)胆固醇的水平方面起关键作用，可作为管理高胆固醇血症的一种治疗选择，旨在降低与高胆固醇水平相关的心血管疾病风险。2023年12月，公司将RBD7022注射液在中国内地、中国香港和中国澳门开发、生产和商业化的独家权利授予齐鲁制药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","III","06938","BK1161"],"gpt_icon":0},{"id":"2614869918","title":"瑞博生物-B02月27日主力净流入2386万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2614869918","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614869918?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:15","pubTimestamp":1772180151,"startTime":"0","endTime":"0","summary":"02月27日, 瑞博生物-B股价涨1.93%，报收68.50元，成交金额2687.6万元，换手率0.23%，振幅2.98%，量比3.18。瑞博生物-B今日主力资金净流入2386万元，上一交易日主力净流出0万元。该股近5个交易日下跌5.45%，主力资金累计净流入2386万元；近20日主力资金累计净流入1868.0万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161942a4cefda1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161942a4cefda1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2614699958","title":"中邮证券：siRNA药物机制优势突出 递送为核心技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2614699958","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614699958?lang=zh_cn&edition=full","pubTime":"2026-02-27 11:04","pubTimestamp":1772161440,"startTime":"0","endTime":"0","summary":"中邮证券发布研报称，siRNA药物可精准沉默致病蛋白，优势显著，递送系统为核心技术。海外巨头基于GalNAc肝递送平台，针对心血管靶点的药物已进入收获期。中邮证券主要观点如下：siRNA药物机制优势突出，递送为核心技术相较于传统小分子和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间长，目前已成为新药开发热门方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227120913a72505ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227120913a72505ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161","01276"],"gpt_icon":0},{"id":"2614772030","title":"国泰海通：FXI引领抗凝药产业新变革 多技术路线竞逐蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2614772030","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614772030?lang=zh_cn&edition=full","pubTime":"2026-02-25 13:37","pubTimestamp":1771997868,"startTime":"0","endTime":"0","summary":"FXI开启抗凝新时代，多技术路线竞逐蓝海研究表明，凝血因子XI是推动病理性血栓的重要因子，但在大多数情况下对正常止血并非必需，比如具有遗传性FXI缺乏的人群，血栓事件的发生率明显降低，而自发性出血的风险并未显著增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023057109.AUD","BK0188","BK0012","LU2543165471.USD","06938","BK0183","BK1147","BK0028","BK0276","02611","BK0184","BK0201","LU0359202008.SGD","01276","BK1161","BK1564","LU0359201885.HKD","601211","BK1191","LU0359201612.USD"],"gpt_icon":0},{"id":"2612230236","title":"中金：首予瑞博生物-B(06938)“跑赢行业”评级 目标价100港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612230236","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612230236?lang=zh_cn&edition=full","pubTime":"2026-02-20 09:58","pubTimestamp":1771552683,"startTime":"0","endTime":"0","summary":"截至25年底，公司已拥有7款进入临床阶段的siRNA管线，其中4款处于II期，RBD4059(FXI)、RBD5044(ApoC3)、RBD1016(HBV)是核心资产。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260220/20260220094929_32902.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260220/20260220094929_32902.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06938"],"gpt_icon":0},{"id":"2611165746","title":"2026年中国生物科技授权交易将迎爆发式增长，有望创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2611165746","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611165746?lang=zh_cn&edition=full","pubTime":"2026-02-13 17:05","pubTimestamp":1770973500,"startTime":"0","endTime":"0","summary":"全球制药企业在专利到期前纷纷削减成本，正加大力度寻找中国研发的创新候选药物，行业分析师预计，今年相关授权交易规模将飙升至历史新高。2026 年至今已宣布38 笔对外授权交易；2025 年全年为186 笔。行业咨询机构 Vision Lifesciences 在 2026 年生物科技授权展望中称，中国在抗体药物偶联物领域全球领先，相关授权交易占全球近90%。首付款大幅上涨随着交易规模扩大，全球药企获取中国药物开发权所需支付的首付款也大幅飙升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213182820a6f7567b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213182820a6f7567b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093","06938","BK1161"],"gpt_icon":0},{"id":"2611165798","title":"近 60 亿美元！不到十天两起小核酸授权出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2611165798","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611165798?lang=zh_cn&edition=full","pubTime":"2026-02-13 07:20","pubTimestamp":1770938451,"startTime":"0","endTime":"0","summary":"根据协议条款，瑞博生物将授予 Madrigal 多款 MASH 领域单靶点及双靶点临床前 siRNA 资产的全球独家研发、生产与商业化权利。Madrigal 的 THR-β 激动剂已经获批上市，用于治疗 MASH，2025 年前三季度销售额 6.4 亿美元，预计全年超过 10 亿美元。这是瑞博生物肝靶向 RiboGalSTAR 平台第二次达成重磅出海合作。早在 2023 年，瑞博生物就此平台与勃林格殷格翰达成共同开发治疗 MASH 的小核酸创新疗法的合作，合作总额超 20 亿美元，成为国内首个向 MNC 许可的 RNAi 技术平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021307240697a5ffdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021307240697a5ffdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2610915655","title":"瑞博生物-B(06938)因悉数行使超额配股权发行474.14万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610915655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610915655?lang=zh_cn&edition=full","pubTime":"2026-02-12 14:11","pubTimestamp":1770876660,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年2月10日根据悉数行使超额配股权而发行及配发474.14万股H股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"1180654376","title":"苏州瑞博生物（06938）更新翌日披露报表，新增4,741,400股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1180654376","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180654376?lang=zh_cn&edition=full","pubTime":"2026-02-12 14:00","pubTimestamp":1770876053,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司（06938）于2026年2月12日发布公告，披露公司已于2026年2月10日根据悉数行使超额配股权，发行并配发4,741,400股H股。该部分新股约占先前已发行股份总数的2.86%，每股发行价为57.97港元。\n本次发行完成后，公司已发行H股股本由165,813,510股增至170,554,910股。公司在公告中确认，本次发行已获得董事会正式授权，并符合香港联合交易所有限公司证券上市规则及相关法律法规的要求。\n上述公告由联席公司秘书张甦签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2610960008","title":"智通港股早知道 | 国务院国资委推动中央企业积极扩大算力有效投资 闪迪(SNDK.US)涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960008","media":"智通财经","labels":["economic"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610960008?lang=zh_cn&edition=full","pubTime":"2026-02-12 07:46","pubTimestamp":1770853599,"startTime":"0","endTime":"0","summary":"国务院国资委推动中央企业积极扩大算力有效投资国务院国资委日前召开中央企业“AI+”专项行动深化部署会。公司董事会表示，上述五个国家和地区对专业化、高品质产后康复服务存在显著且未被充分满足的需求。毛利润为约人民币 177 亿元，同比增加 8.7%。归属于公司股东的净利润为人民币62.42亿元。第四季度股利为每股 0.232 美元。其中，游戏及相关增值服务净收入为人民币 220 亿元，同比增加 3.4%。有道净收入为人民币 16 亿元，同比增加 16.8%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","LU0231459107.USD","VXUS","BK1615","BK1128","BK4170","LU0278937759.USD","BK4585","BK1161","BK4588","VT","IE0009570106.USD","09899","SNDK"],"gpt_icon":0},{"id":"1100910072","title":"瑞博生物与瑞博制药宣布与Madrigal就靶向MASH的新型siRNA疗法达成独家全球许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1100910072","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100910072?lang=zh_cn&edition=full","pubTime":"2026-02-11 19:26","pubTimestamp":1770809176,"startTime":"0","endTime":"0","summary":"瑞博生物（股票代码：06938）与瑞博制药（RIBOLIFE-B）今日宣布，已与Madrigal Pharmaceuticals（股票代码：MDGL）就针对代谢功能障碍相关脂肪性肝炎（MASH）的新型小干扰RNA（siRNA）疗法签署独家全球许可协议。\n根据协议条款，Madrigal将获得上述siRNA疗法在全球范围内的独家开发及商业化权利。此次合作旨在加速该创新疗法的研发进程，为MASH患者提供潜在的新型治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","MDGL","BK4588","BK1161","BK4585","BK4139"],"gpt_icon":0},{"id":"1110422658","title":"瑞博生物与Madrigal就多款siRNA资产达成全球独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1110422658","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110422658?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:09","pubTimestamp":1770804580,"startTime":"0","endTime":"0","summary":"苏州瑞博生命科学股份有限公司（以下简称“瑞博生物”）近日宣布，已与美国生物技术公司Madrigal Pharmaceuticals达成一项全球独家授权协议。根据协议内容，瑞博生物将授予Madrigal在全球范围内开发、生产和商业化多款小干扰RNA（siRNA）候选药物的独家权利。\n此次合作涉及的siRNA资产覆盖多个治疗领域，有望为相关疾病患者提供新的治疗选择。通过这项授权协议，瑞博生物将进一步拓展其创新药物的国际化布局，加速核心技术的商业化进程。Madrigal将凭借其在代谢性疾病领域的专业优势，推动这些siRNA资产的临床开发和市场应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1148640471","title":"瑞博生物-B达成6项代谢功能障碍相关脂肪性肝炎临床前siRNA项目授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1148640471","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148640471?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:05","pubTimestamp":1770804310,"startTime":"0","endTime":"0","summary":"苏州瑞博生命科学（瑞博生物-B）近日宣布，已就6项针对代谢功能障碍相关脂肪性肝炎（MASH）治疗的临床前阶段小干扰RNA（siRNA）研发项目达成授权许可协议。该交易标志着公司在核酸药物研发领域，特别是在代谢性疾病治疗方向的战略布局取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4588","MDGL","BK4139","06938","BK4585"],"gpt_icon":0},{"id":"2610933555","title":"瑞博生物-B(06938)就若干siRNA资产与Madrigal订立独家全球授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2610933555","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610933555?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:03","pubTimestamp":1770804224,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，于2026年2月11日，本公司及其附属公司Ribocure Pharmaceuticals AB与Madrigal Pharmaceuticals, Inc. 就开发六款针对代谢功能障碍相关脂肪性肝炎的临床前小干扰核酸疗法订立独家全球授权协议(该协议)。根据该协议，本公司已授予Madrigal独家全球授权，以运用本公司的 RiboGalSTARTM及siRNA化学修饰平台，开发、生产及商业化若干临床前单靶点及双靶点siRNA资产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B(06938)就若干siRNA资产与Madrigal订立独家全球授权协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2610946426","title":"港股异动 | 瑞博生物-B(06938)涨超5% RBD5044  II期临床试验获默示许可 全球小核酸药物迎来蓬勃发展期","url":"https://stock-news.laohu8.com/highlight/detail?id=2610946426","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610946426?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:33","pubTimestamp":1770694416,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞博生物-B涨超5%，截至发稿，涨5.62%，报72.45港元，成交额648.3万港元。消息面上，近日，瑞博生物-B发布公告，本集团自主研发的RBD5044注射液已获中国国家药品监督管理局的II期临床试验默示许可。RBD5044是一款靶向APOC3的siRNA药物。国盛证券认为，小核酸药物正迎来全球范围内的蓬勃发展期，已从技术验证阶段迈入临床兑现与商业化加速阶段。该行指出，目前全球小核酸累计获批上市药物已达23款，覆盖siRNA、ASO、适配体等多个技术方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK4588","VXUS","BK1161","BK4585","VT"],"gpt_icon":0},{"id":"2609097903","title":"瑞博生物-B(06938)：超额配股权获悉数行使 稳定价格期结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2609097903","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609097903?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:35","pubTimestamp":1770302154,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)公布，整体协调人(为其本身及代表国际承销商)已于2026年2月5日(星期四)悉数行使招股章程所述的超额配股权，涉及合共474.14万股H股，占于任何超额配股权获行使前全球发售项下可供认购发售股份总数约15%(经计及发售量调整权获悉数行使)。超额配发股份将由公司按每股H股57.97港元发行及配发。超额配发股份将用于补足国际发售的超额分配。此外，有关全球发售的稳定价格期已于2026年2月5日(星期四)(即递交香港公开发售申请截止日期后第30日)结束。于稳定价格期，稳定价格操作人并无为稳定价格而在市场上买卖任何H股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2608331010","title":"【IPO月报】港股IPO市场1月热度延续 13家企业登录港交所无一破发","url":"https://stock-news.laohu8.com/highlight/detail?id=2608331010","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608331010?lang=zh_cn&edition=full","pubTime":"2026-02-04 13:19","pubTimestamp":1770182397,"startTime":"0","endTime":"0","summary":"进入2026年1月，这一强劲势头得到进一步延续和强化，当月共有13家企业成功登陆港交所，其中12家登陆主板、1家登陆创业板，募资总额达382亿港元，开局表现亮眼，13家公司鸣“锣”当日均以涨幅收盘，无一破发，相较上月气氛显著转好。截至2025年12月31日，已有16宗港股上市申请被暂停审理。此次壁仞科技以19.60港元的发行价登陆港交所，募资55.83亿港元，成为当月募资王。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/OWY3M2YyZDg0YWFmYjQ5NTRjZGVkOGJjMDhiNTg2MTM1NjQyMDU4NTg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OWY3M2YyZDg0YWFmYjQ5NTRjZGVkOGJjMDhiNTg2MTM1NjQyMDU4NTg=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974551","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1132","BK4585","08610","01641","06938","BK1163","BK1128","BK1117","VXUS","BK1161","BK4588","VT","BK1193","03636","HEXmain","02675","09611","00501"],"gpt_icon":1},{"id":"2607073008","title":"Tides 周递 | 全球多肽和寡核苷酸药物一周要闻（1.22-1.30）","url":"https://stock-news.laohu8.com/highlight/detail?id=2607073008","media":"多肽圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607073008?lang=zh_cn&edition=full","pubTime":"2026-01-31 09:00","pubTimestamp":1769821223,"startTime":"0","endTime":"0","summary":"Brenipatide 是一款 GLP1R/GIPR 双激动剂，也是继替尔泊肽后，礼来第二款 GLP-1/GIP 双靶点新药。替尔泊肽 2025 年前三季度大卖了 248 亿美元，同比增长 125%。2023年12月，罗氏出手31亿美元收购Carmot Therapeutics，获得了该公司旗下的多款肠促胰岛素药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260131091614a6c20546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260131091614a6c20546&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0314109678.HKD","LU1328277881.USD","LU0067412154.USD","LU1993786604.SGD","LU1152091168.USD","LU1226288253.USD","IE0008368742.USD","LU1226287792.SGD","IE0008369823.USD","HK0000165453.HKD","IE00B5MMRT66.SGD","LU1152091754.HKD","LU0140636845.USD","LU0880133367.SGD","BK1191","LU1960683339.HKD","BK1515","IE00B543WZ88.USD","LU0326950275.SGD","LU1226287529.USD","IE00BZ08YS42.EUR","LU1008478684.HKD","SG9999004220.SGD","LU0501845795.SGD","IE00BZ08YR35.GBP","01276","LU1226288170.HKD","LU1813983027.USD","LU1807302812.USD","BK1521","06938","LU2039709279.SGD","01093","IE00BZ08YT58.USD","LU1951186391.HKD","LU0315179316.USD","LU0072913022.USD","LU1226287875.USD","IE00B031HY20.USD"],"gpt_icon":0},{"id":"2607078516","title":"瑞博生物-B01月30日遭主力抛售27.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607078516","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607078516?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:15","pubTimestamp":1769760947,"startTime":"0","endTime":"0","summary":"01月30日, 瑞博生物-B股价跌5.75%，报收68.80元，成交金额5345.3万元，换手率0.47%，振幅7.40%，量比2.05。瑞博生物-B今日主力资金净流出27.2万元，连续4日净流出，上一交易日主力净流出154.3万元。该股近5个交易日下跌11.94%，主力资金累计净流出469.5万元；近20日主力资金累计净流出3623.7万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130162310a6bf38d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130162310a6bf38d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06938"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":-0.1469},{"period":"1month","weight":-0.1134},{"period":"3month","weight":0.0523},{"period":"ytd","weight":0.0523}],"compareEarnings":[{"period":"1week","weight":-0.0309},{"period":"1month","weight":-0.0591},{"period":"3month","weight":0.0003},{"period":"6month","weight":0.0283},{"period":"1year","weight":0.12},{"period":"ytd","weight":0.0054}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州瑞博生物技术股份有限公司是一家主要从事小核酸药物研究和开发，尤其专注于小干扰核酸（siRNA）疗法的中国公司。该公司的主营业务是从事小核酸药物的创新，专注于心血管、代谢类、肾脏和肝病以及其他治疗领域。该公司的药物管线包括RBD4059、RBD5044、RBD7022、RBD7007、RBD2080、RBD1119、RBD1016等。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"瑞博生物-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞博生物-B,06938,瑞博生物-B股票,瑞博生物-B股票老虎,瑞博生物-B股票老虎国际,瑞博生物-B行情,瑞博生物-B股票行情,瑞博生物-B股价,瑞博生物-B股市,瑞博生物-B股票价格,瑞博生物-B股票交易,瑞博生物-B股票购买,瑞博生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}